Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - REVIVA PHARMACEUTICALS HOLDINGS, INC. | tm2016903d1_ex32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - REVIVA PHARMACEUTICALS HOLDINGS, INC. | tm2016903d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - REVIVA PHARMACEUTICALS HOLDINGS, INC. | tm2016903d1_ex31-1.htm |
| EX-4.5 - EXHIBIT 4.5 - REVIVA PHARMACEUTICALS HOLDINGS, INC. | tm2016903d1_ex4-5.htm |
| 10-K - FORM 10-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. | tm2016903d1_10k.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADDED BY
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Tenzing Acquisition Corp. (the “Company”) on Form 10-K for the annual period ended February 29, 2020, as filed with the Securities and Exchange Commission (the “Report”), I, Rahul Nayar, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report. |
Date: May 1, 2020
| By: | /s/ Rahul Nayar | |
|
Rahul Nayar Chief Executive Officer |
||
| (Principal Executive Officer) |